{{ currentBoardShortName }}
  • Markets
  • Indices
  • FX
  • Energy
  • Metals
Markets
As of: {{timeStamp.date}}
{{timeStamp.time}}

Markets

{{ currentBoardShortName }}
  • Markets
  • Indices
  • FX
  • Energy
  • Metals
{{data.symbol | reutersRICLabelFormat:group.RICS}}
 
{{data.netChng | number: 4 }}
{{data.netChng | number: 2 }}
{{data | displayCurrencySymbol}} {{data.price | number: 4 }}
{{data.price | number: 2 }}
{{data.symbol | reutersRICLabelFormat:group.RICS}}
 
{{data.netChng | number: 4 }}
{{data.netChng | number: 2 }}
{{data | displayCurrencySymbol}} {{data.price | number: 4 }}
{{data.price | number: 2 }}

Commodities Videos

VIDEO SIGN OUT

{{ currentStream.Name }}

{{ currentStream.Desc }}

Related Video

Continuous Play:
ON OFF

The information you requested is not available at this time, please check back again soon.

From aluminum to zinc and everything in between, join BNN for the latest insight into the hot world of commodities and the companies that produce them, including interviews with mineral and mining entrepreneurs from Canada and around the globe. Whether it's a gold play in the Andes or a hot offshore oil prospect, BNN has you covered on commodities. 

 

Email: commodities@bnn.ca

Dec 1

Canopy Growth to acquire rival pot producer Mettrum for $430M in stock

VIDEO SIGN OUT

Security Not Found

The stock symbol {{StockChart.Ric}} does not exist

See Full Stock Page »

Canada’s largest publicly-traded medical marijuana company Canopy Growth (CGC.TO) announced early Thursday it has agreed to acquire rival Mettrum Health (MT.V) for $430 million in stock.

Mettrum shareholders will be entitled to receive 0.7132 of a common share of Canopy under the offer, which would create a company with six facilities licensed to produce medical marijuana products.

Canopy's offer values Mettrum shares at $8.42 -- $2.50 above the closing stock price Wednesday.

Assuming the deal gets shareholder approvals at both companies, Mettrum will become a wholly owned subsidiary of Canopy and Mettrum shareholders will own about 22.3 per cent of the combined company.

The acquisition of Toronto-based Mettrum will form a marijuana company that serves half of Canada’s medial pot users. Canopy Growth said the deal would increase its production capacity to six licensed facilities, bringing the company’s total footprint to about 665,000 square feet with “significant acreage for expansion.”

With the purchase of Mettrum, Smith Falls, Ont.-based Canopy Growth said it will be able to expand its portfolio of cannabis and hemp brands to include Mettrum Spectrum and Mettrum Originals. Canopy Growth’s marijuana brands currently include its medical line Bedrocan Canada and the lifestyle-focused Tweed brand.

"Mettrum has established a line of cannabis products that work well in a medical context and will transition naturally into a natural and healthy lifestyle market,” Bruce Linton, chairman and CEO of Canopy Growth, said in a release. 

“Their substantial production facilities will add to our growing production platform as we expand to meet the needs of patients, and their experienced personnel will help Canopy Growth drive our vision forward to the next level."

A task force studying the legalization of marijuana in Canada said it will deliver its findings to Prime Minister Justin Trudeau's cabinet and the public in two weeks. 

The takeover comes three days after Canopy announced an agreement to buy German pharmaceutical distributor MedCann in an all-stock transaction worth about $7.2 million. 

Canopy and Mettrum shareholders will vote on the deal at a special meeting in January.

Mettrum's board has agreed to pay Canopy a $10-million termination fee under certain circumstances if the deal doesn't go through. Canopy will also have the right to match a superior proposal from a rival buyer.

With files from The Canadian Press

What you need to know before investing in marijuana stocks

Dundee Capital Markets research analyst Daniel Pearlstein tells BNN about everything you need to know about investing in marijuana stocks including the regulatory risks, competition in the sector and the addressable markets.